CEO, Phrenix Therapeutics
| Role | Organisation | Sources |
|---|---|---|
| Deputy Director (former) | Monash University | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
| Chief Executive (former) | Phrenix | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
| CEO | Phrenix Therapeutics | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
Stories naming Professor Chris Langmead. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brandon BioCatalyst's CUREator incubator names its first-round awardees, distributing government-backed funding across 23 Australian life science companies working on treatments from schizophrenia to diabetes, with round two applications now open.
The CUREator incubator, run by Brandon BioCatalist's partner organisation, names its first-round awardees, distributing government-backed grant funding across 23 Australian life science companies developing treatments for diseases including diabetes, cancer and COPD.
Biotech incubator CUREator has awarded its first grants, totalling $17.4 million, to 23 early-stage medical startups including Phrenix and RAGE Biotech, aiming to ready them for commercial investment.